2024-512390-27-00招募中1 期
A first-in-human dose escalation and expansion study with the SIRPα-directed monoclonal antibody BYON4228 alone and in combination with rituximab to evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy in patients with relapsed/refractory CD20 positive B-cell Non-Hodgkin’s Lymphoma (NHL)
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- Byondis B.V.
- 入组人数
- 66
- 试验地点
- 10
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Clinical Development
Scientific
Byondis B.V.
研究点 (10)
Loading locations...
相似试验
已完成
1 期
A first in human single dose escalation study to investigate the safety, tolerability, pharmacokinetics, and pharmcodynamics of BAY 3389934 compared with placebo.2022-502866-25-00Bayer AG86
招募中
1/2 期
A phase I dose-escalation study testing the feasibility and the tolerance of infusion of a third party suicide gene-transduced anti-HLA-DPB1*0401 cytotoxic T cell clone in patients with HLA-DPB1*0401 positive hematologic malignancies and receiving an allotransplant from HLA-DPB1*0401 negative donors2024-515504-39-00Centre Hospitalier Universitaire De Nantes6
招募中
2 期
A first-in-human, dose escalation and dose expansion study of SAR445877 in adult participants with advanced solid tumors2023-507141-28-00Sanofi-Aventis Recherche & Developpement115
尚未招募
1 期
A First-in-Human Study to Evaluate the Administration of ReoCure alone and in combination with Keytruda (Pembrolizumab) in Patients with Advanced Malignant Solid TumoursAdvanced Malignant Solid TumoursCancer - Any cancerACTRN12620000777998ViroCure, Inc.45
招募中
不适用
A first-in-human dose-escalation and expansion study with the antibody-drug conjugate BYON3521 to evaluate the safety, pharmacokinetics and efficacy in patients with c-MET expressing locally advanced or metastatic solid tumours.cancerNL-OMON56017Fortrea Belgium SR36